These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20886218)

  • 1. Collagenase-3 expression by tumor cells and gelatinase B expression by stromal fibroblast-like cells are associated with biochemical recurrence after radical prostatectomy in patients with prostate cancer.
    Escaff S; Fernández JM; González LO; Suárez A; González-Reyes S; González JM; Vizoso FJ
    World J Urol; 2011 Oct; 29(5):657-63. PubMed ID: 20886218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer.
    Cardillo MR; Di Silverio F; Gentile V
    Anticancer Res; 2006; 26(2A):973-82. PubMed ID: 16619495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of TIMP-1 immune expression and tumor recurrence in localized prostate cancer.
    Reis ST; Viana NI; Iscaife A; Pontes-Junior J; Dip N; Antunes AA; Guimarães VR; Santana I; Nahas WC; Srougi M; Leite KR
    Int Braz J Urol; 2015; 41(6):1088-95. PubMed ID: 26742965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinases and angiogenic factors: predictors of survival after radical prostatectomy for clinically organ-confined prostate cancer?
    Boxler S; Djonov V; Kessler TM; Hlushchuk R; Bachmann LM; Held U; Markwalder R; Thalmann GN
    Am J Pathol; 2010 Nov; 177(5):2216-24. PubMed ID: 20889560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of stromal metalloproteases expression in patients with benign hyperplasia and prostate cancer.
    Escaff S; Fernández JM; González LO; Suárez A; González-Reyes S; González JM; Vizoso FJ
    J Cancer Res Clin Oncol; 2011 Mar; 137(3):551-5. PubMed ID: 20508949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    Miyake H; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
    Urol Oncol; 2010; 28(2):145-51. PubMed ID: 18848789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of biochemical recurrence after robot-assisted radical prostatectomy: analysis of 784 Japanese patients.
    Hashimoto T; Yoshioka K; Nagao G; Nakagami Y; Ohno Y; Horiguchi Y; Namiki K; Nakashima J; Tachibana M
    Int J Urol; 2015 Feb; 22(2):188-93. PubMed ID: 25339062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between metalloprotease expression in tumour and stromal cells and aggressive behaviour in prostate carcinoma: Simultaneous high-throughput study of multiple metalloproteases and their inhibitors using tissue array analysis of radical prostatectomy samples.
    Fernandez-Gomez J; Escaf S; Gonzalez LO; Suarez A; Gonzalez-Reyes S; González J; Miranda O; Vizoso F
    Scand J Urol Nephrol; 2011 Apr; 45(3):171-6. PubMed ID: 21244194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?
    Sokoll LJ; Zhang Z; Chan DW; Reese AC; Bivalacqua TJ; Partin AW; Walsh PC
    J Urol; 2016 Feb; 195(2):330-6. PubMed ID: 26307160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
    Sakai I; Harada K; Kurahashi T; Muramaki M; Yamanaka K; Hara I; Inoue TA; Miyake H
    Urol Int; 2006; 76(3):227-31. PubMed ID: 16601384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Risk factors for biochemical recurrence after radical prostatectomy in patients with clinically localized prostate cancer. Implications of adjuvant treatment].
    Fagundo EV; Amo FH; López EL; Sánchez JP; Jiménez Gdel P; Chamizo JA; Cordero JM; Fernández ME; Fernández CH
    Arch Esp Urol; 2012; 65(1):158-65. PubMed ID: 22318186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion.
    Di Nezza LA; Misajon A; Zhang J; Jobling T; Quinn MA; Ostör AG; Nie G; Lopata A; Salamonsen LA
    Cancer; 2002 Mar; 94(5):1466-75. PubMed ID: 11920503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence.
    Shikanov S; Song J; Royce C; Al-Ahmadie H; Zorn K; Steinberg G; Zagaja G; Shalhav A; Eggener S
    J Urol; 2009 Jul; 182(1):139-44. PubMed ID: 19450829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum prostate-specific antigen value adjusted for non-cancerous prostate tissue volume in patients undergoing radical prostatectomy: a new predictor of biochemical recurrence in localized or locally advanced prostate cancer.
    Ku JH; Moon KC; Cho SY; Kwak C; Kim HH
    Asian J Androl; 2011 Mar; 13(2):248-53. PubMed ID: 21102474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.